Stay updated with breaking news from Appendix Table. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Reporting on the real-world utilization of reference rituximab and its biosimilars can help show prescribing habits and reveal cost-saving opportunities.
Formulary restrictions can create treatment barriers for patients with atrial fibrillation, including unnecessary delays in treatment and prescription abandonment, with vulnerable populations at greater risk.
Increases 2023 Share Repurchases to $1.15 Billion Increases 2023 Guidance Initiates Strong 2024 Financial Guidance Above 2023 Investor Day Plan Solid third quarter performance with GAAP Net...
/PRNewswire/ -- Ecovyst Inc. (NYSE: ECVT) ("Ecovyst" or the "Company"), a leading integrated and innovative global provider of specialty catalysts and...
A difference-in-differences analysis of health care claims data evaluated excess health care costs in the 12 months following COVID-19 diagnosis among the general and older adult populations.